Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00485862 · ClinicalTrials.gov registry record · Phase 4

Combination Therapy in Patients With Depression

A Phase 4 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 4
Development phase
214
Enrollment target

NCT00485862 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 214 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00485862, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 4
Development phase
214 participants
Enrollment target

Study Summary

The purpose of the study is to compare sertraline and atomoxetine/sertraline combination therapy in patients with persistent depressive symptoms.

Interventions

  • DRUG Placebo
  • DRUG Sertraline
  • DRUG Atomoxetine Hydrochloride

Trial Details

FieldValue
Enrollment Target 214 participants
Start Date 2003-06
Est. Completion 2005-01
Phase Phase 4

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT00485862

The ClinicalTrials.gov registry entry for NCT00485862 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00485862 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00485862 about?

NCT00485862 is a clinical study titled "Combination Therapy in Patients With Depression". The purpose of the study is to compare sertraline and atomoxetine/sertraline combination therapy in patients with persistent depressive symptoms.

What is the current status of trial NCT00485862?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 214 participants. The study started on 2003-06. Estimated completion is 2005-01.

What interventions are being tested in trial NCT00485862?

The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG), Atomoxetine Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00485862?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.